The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia
Files
Publication date
2016-08-15
Authors
François, Bruno
Chastre, Jean
Eggiman, Philippe
Laterre, Pierre-François
Torres, Antoni
Sanchez, Miguel
Esser, Mark T
Bishop, Brian
Bonten, Marc
Goosens, Herman
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
The Innovative Medicines Initiative-funded COMBACTE consortium fosters academic-industry partnership in pioneering studies to combat serious bacterial infections. We describe how this partnership is advancing the development of 2 monoclonal antibodies, MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.
Keywords
nosocomial pneumonia, ventilator-associated pneumonia, monoclonal antibody, ICU, Journal Article
Citation
François, B, Chastre, J, Eggiman, P, Laterre, P-F, Torres, A, Sanchez, M, Esser, M T, Bishop, B, Bonten, M, Goosens, H & Jafri, H S 2016, 'The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium : A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia', Clinical Infectious Diseases, vol. 63 , no. Suppl 2, pp. S46-S51. https://doi.org/10.1093/cid/ciw245